Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/81341
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Author: Ross, D.
Branford, S.
Seymour, J.
Schwarer, A.
Arthur, C.
Yeung, D.
Dang, P.
Goyne, J.
Slader, C.
Filshie, R.
Mills, A.
Vaz de Melo, J.
White, D.
Grigg, A.
Hughes, T.
Citation: Blood, 2013; 122(4):515-522
Publisher: Amer Soc Hematology
Issue Date: 2013
ISSN: 0006-4971
1528-0020
Statement of
Responsibility: 
David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, and Timothy P. Hughes
Abstract: Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 chronic-phase CML patients who had sustained undetectable minimal residual disease (UMRD) by conventional quantitative polymerase chain reaction (PCR) on imatinib for at least 2 years. Patients stopped imatinib and were monitored frequently for molecular relapse. At 24 months, the actuarial estimate of stable treatment-free remission was 47.1%. Most relapses occurred within 4 months of stopping imatinib, and no relapses beyond 27 months were seen. In the 21 patients treated with interferon before imatinib, a shorter duration of interferon treatment before imatinib was significantly associated with relapse risk, as was slower achievement of UMRD after switching to imatinib. Highly sensitive patient-specific BCR-ABL DNA PCR showed persistence of the original CML clone in all patients with stable UMRD, even several years after imatinib withdrawal. No patients with molecular relapse after discontinuation have progressed or developed BCR-ABL mutations (median follow-up, 42 months). All patients who relapsed remained sensitive to imatinib re-treatment. These results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse.
Keywords: Humans; Neoplasm, Residual; Disease Progression; Recurrence; Benzamides; Piperazines; Pyrimidines; Antineoplastic Agents; Disease-Free Survival; Treatment Outcome; Withholding Treatment; Follow-Up Studies; Adult; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rights: © 2013 by The American Society of Hematology
RMID: 0020131772
DOI: 10.1182/blood-2013-02-483750
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.